Absorptive Clearance in the Cystic Fibrosis Airway

Plain-language summary

This study looks at how fluid in the airways is cleared through absorption in people with cystic fibrosis and in healthy volunteers, using labeled tracer substances (Technetium [Tc-99m] sulfur colloid and Indium [In-111] DTPA). Clinically stable people aged 18 and older diagnosed with cystic fibrosis by sweat test or genotype, as well as healthy controls, could take part. This was a study without a phase and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

Not Applicable

Status

Completed

Sponsor

University of Pittsburgh

Intervention

Technetium [Tc-99m] sulfur colloid and Indium [In-111] DTPA

Start date

10/1/2007

Estimated completion

4/1/2008

Countries

United States

Related genes

Locations

• Pittsburgh, United States

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Cystic fibrosis subjects and healthy controls
* Age ≥ 18 years
* Diagnosis of cystic fibrosis as determined by sweat test or genotype and clinical symptoms (CF subjects)
* Clinically stable as determined by the investigator (pulmonologist)

Exclusion Criteria:

* Reactive airways disease
* Tobacco smokers (regular smoking within 6 months of enrollment)
* Positive urine pregnancy test on the day of testing
* FEV1p value of \< 50%
* SaO2 \< 92%, or if they require supplemental oxygen.
* Subjects performing other radioisotope studies within the last 2 weeks will be excluded.
* Healthy subjects with any history of lung disease will be excluded.
* Women currently breastfeeding
* Subjects not willing to stop treatments with inhaled hypertonic saline for 48 hours in advance of the study.